ESMO 2023 | SKB264 (TROP2-ADC) Shows Promise in the Treatment of HR+/HER2- Metastatic Breast Cancer, Advancing in Multiple Cancer Types
TROP2 (Trophoblast Cell-Surface Antigen 2) is highly expressed in various solid tumors, making it a hot target in the field of oncology. The development of antibody-drug conjugates (ADCs) targeting this antigen has garnered significant attention. At the 2023 European Society for Medical Oncology (ESMO) Congress held in Madrid, Spain from October 20th to 24th, an innovative TROP2-ADC called SKB264 (MK-2870), jointly developed by CoromboTech and Merck, was presented in an oral report from a phase I/II basket trial for the treatment of advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) (Abstract number: 380MO). The study results confirm that SKB264 exhibits manageable safety and significant anti-tumor activity in HR+/HER2- metastatic breast cancer patients. Professor Yongmei Yin presented the research and its key findings at the conference.